Rochester's Bachelor Forum, oldest gay bar, celebrates golden anniversary
Rochester's oldest gay bar, The Bachelor Forum, celebrated its 50th anniversary on Saturday.
Source: 13wham.com
Peter Mohr News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Peter Mohr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Peter Mohr Today - Breaking & Trending Today
Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023
First presentation of results from CheckMate -901 show survival benefit with Opdivo + chemotherapy in the first-line treatment of patients with unresectable or metastatic urothelial carcinoma who...
Source: marketscreener.com
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Tre
Approval based on results from the Phase 3 CheckMate -76K trial in patients with stage IIB or IIC melanoma, in which Opdivo reduced the risk of recurrence or death by 58% versus placeboOpdivo is the only PD-1 inhibitor that is indicated as an adjuvant treatment for patients within stages IIB, IIC, III, as well as st...
Source: pharmiweb.com
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
22.08.2023 - Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) as a monotherapy for the adjuvant treatment of adults and adolescents 12 years of age and older with stage IIB or IIC melanoma who ...
Source: wallstreet-online.de
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma   -Today at 04:19 pm
Approval based on results from the Phase 3 CheckMate -76K trial in patients with stage IIB or IIC melanoma, in which Opdivo reduced the risk of recurrence or death by 58% versus placebo Opdivo is...
Source: marketscreener.com